Top Casino Stocks To Invest In 2019

Federal investigators have halted an alleged student loan debt relief scam that bilked more than $11 million from consumers nationwide.

Strategic Student Solutions and several related companies falsely promised to reduce or eliminate student loan debt and also offered the borrowers non-existent credit repair services, in exchange for upfront fees and monthly payments, the Federal Trade Commission charged incourt papersmade public Thursday.

Although borrowers allegedly got no relief from their debts, Dave Green, owner of the companies, used corporate funds to pay for jewelry, casino tabs, mortgage payments, luxury vehicles and construction of a pool, the FTC charged.

.oembed-asset-link { border-bottom: 1px solid #e1e1e1; } .oembed-link-anchor { display: block; clear: both; } p.oembed-link-desc { font-size: 100%; color: #666; font-weight: normal; margin: 0 14px 14px 14px; font-family: ‘Futura Today Light’; text-align: left; line-height: 120%; }

FTC Complaint v Strategic Student Solutions

Top Casino Stocks To Invest In 2019: City Holding Company(CHCO)

Advisors’ Opinion:

  • [By Monica Gerson]

    City Holding Company (NASDAQ: CHCO) is expected to report its quarterly earnings at $0.74 per share on revenue of $42.04 million.

    Compass Minerals International, Inc. (NYSE: CMP) is projected to post its quarterly earnings at $1.33 per share on revenue of $347.03 million.

Top Casino Stocks To Invest In 2019: Richmont Mines, Inc.(RIC)

Advisors’ Opinion:

  • [By Sally Jones]

    Richmont Mines Inc. (RIC)

    Down 70% over 12 months, Richmont Mines Inc. has a market cap of $56.23 billion, and trades with a P/B of 0.60.

Top Casino Stocks To Invest In 2019: Prothena Corporation plc(PRTA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Prothena Corporation plc (NASDAQ: PRTA) shares dipped 69 percent to $11.48 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction.
    Gridsum Holding Inc. (NASDAQ: GSUM) fell 44.3 percent to $4.06. Gridsum reported suspension of audit report on financial statements.
    Flotek Industries, Inc. (NYSE: FTK) shares declined 34.1 percent to $4.16 as the company issued weak revenue forecast for the first quarter.
    Akorn, Inc. (NASDAQ: AKRX) dropped 32.3 percent to $13.35 after Fresenius terminated its merger deal with Akorn.
    Chicago Bridge & Iron Company N.V. (NYSE: CBI) fell 31.2 percent to $13.44. Subsea 7 made an unsolicited bid to buy McDermott for $7 per share. However, the acquisition offer is contingent on McDermot terminating its pending merger with Chicago Bridge & Iron.
    Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS) dropped 18 percent to $5.76. Controladora Vuela recently reported first-quarter results that showed a loss for the quarter. Imperial Capital downgraded Controladora Vuela Compania de Aviacion from Outperform to In-Line.
    Atossa Genetics Inc. (NASDAQ: ATOS) fell 18.2 percent to $2.8797 after declining 19.35 percent on Friday.
    Alcoa Corporation (NYSE: AA) fell 12.3 percent to $52.63.
    Luby's, Inc. (NYSE: LUB) shares declined 10.3 percent to $2.448 following Q2 results.
    Aceto Corporation (NASDAQ: ACET) shares tumbled 10 percent to $2.26.
    Pier 1 Imports, Inc. (NYSE: PIR) dipped 9.7 percent

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Jon C. Ogg]

    Creating a treatment for a rare disease or rare disorder can come with massive upside if the treatment is successful. That said, the risk is that a company can implode if its rare disease treatment fails in a drug study. Now it looks as if Prothena Corporation plc (NASDAQ: PRTA) is on the verge of implosion based upon how its stock price reacted.

  • [By Brian Feroldi]

    In response to announcingthat it is stopping all clinical development of its lead product candidate,Prothena(NASDAQ:PRTA), a clinical-stage biotech focused onneuroscience andorphandiseases, saw its shares fall 69% as of 11 a.m. EDT.

  • [By Paul Ausick]

    Prothena Corp. plc (NASDAQ: PRTA) traded down 70% Monday to post a new 52-week low of $11.05 after closing Friday at $36.84. The stock’s 52-week high is $70.00. Volume was more than 20 times the daily average of around 580,000 shares. The company is stopping development on an amyloidosis treatment following a failed late-stage trial.

  • [By Lisa Levin]

    Prothena Corporation plc (NASDAQ: PRTA) shares dropped 69 percent to $11.43 after a disappointing update relating to the company's treatment for AL amyloidosis. Prothena, a clinical-stage biopharmaceutical company that focuses on therapies in the neuroscience and orphan categories, said a Phase 2b study of its therapy called NEOD001 failed to achieve its primary or secondary endpoints. Prothena's Phase 2b study explored its NEOD001 therapy versus a placebo in previously-treated patients with AL amyloidosis and persistent cardiac dysfunction. Unfortunately, there were no statistically significant difference between the two treatment groups.

Leave a Reply

Your email address will not be published. Required fields are marked *